Released Nov 5, 2026, after the close
10-Q filed Nov 5, 2026, 36 days after period end · 0001636422-26-000125
What the release said
On November 5, 2026, Health Catalyst, Inc. (the “Company”) issued a press release relating to its financial results for the quarter ended September 30, 2026.
Total revenue for the three months ended September 30, 2026 was 56,283 in thousands, down 26% from 76,323, while net income was 40,496 in thousands, largely driven by a $65.9 million gain on sale of the Vitalware Business.¶2¶3¶4
Adjusted EBITDA for the three months ended September 30, 2026 was 12,000 in thousands, down 94%, with the decline attributed primarily to the divestiture of the Vitalware Business on July 31, 2026 and migration headwinds from DOS to Ignite.¶5¶4
The Vitalware Transaction closed on July 31, 2026 with total consideration received of $146.3 million, and the company used the net cash proceeds with cash on hand to repay in full all obligations under the Credit Agreement.¶6¶7
- Full-year 2026 total revenue outlook
- $246 million to $249 million¶8
- Full-year 2026 Adjusted EBITDA outlook
- $18 million to $18.5 million¶9
- Gain on sale of the Vitalware Business
- $65.9 million Three months ended September 30, 2026; drove net income¶4
- Total consideration received, Vitalware Transaction
- $146.3 million Transaction closed July 31, 2026; $80.4 million of net assets disposed¶6
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $56.28M | $76.32M | $76.35M | $73.77M |
| Net Income | $40.50M | -$22.23M | -$14.73M | -$22.03M |
| EPS Diluted | $0.53 | -$0.32 | -$0.24 | -$0.39 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Health Catalyst, Inc. · CIK 1636422 · Engraved from SEC EDGAR